A year has passed since I penned a glowing assessment of Illumina, a biotech giant that has continued to shine brightly. For those looking to refresh their knowledge, I recommend revisiting that earlier piece as a precursor to this update. Since then, Illumina’s stock has delivered a remarkable 25% total return, buoyed in part by the promising prospects of its subsidiary, GRAIL.
As a disclosure, I hold a long position in Illumina through various means, including stock ownership, options, and derivatives. My opinions are my own, and I receive no compensation for this article beyond what is provided by Seeking Alpha. I have no business ties to any companies mentioned in this piece. It’s essential to remember that past successes do not guarantee future outcomes, and individual investors should carefully consider their unique circumstances before making any investment decisions. The views expressed here are solely my own and may not reflect those of Seeking Alpha as a whole.
Leave a Reply